Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06611345
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
A Study of Tumor-Treating Fields in Combination With Durvalumab and GemcitabineCisplatin in Biliary Tract Cancers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-Arm Phase 1b Study to Assess Tumor-Treating Fields TTF in Combination With Durvalumab and GemcitabineCisplatin GemCis as the First-Line Treatment of Unresectable Biliary Tract Cancers BTC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Unresectable BTC represents an area of unmet medical need due to its very aggressive nature limited treatment options and poor prognosis This study is to evaluate the efficacy and safety of adding TTF to the established regimen of durvalumab plus GemCis for the treatment of patients with previously untreated unresectable BTC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None